why choose us

First received: August 21, 2023

Clinical Trial: A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Esophageal Cancer
Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma by

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of LBL-007 in Combination With Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With Un

Brief Summary: This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Read more